(VIANEWS) – Mercury General Corporation (MCY), Molina Healthcare (MOH), Ceragon Networks Ltd. (CRNT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Mercury General Corporation (MCY)
29.3% sales growth and 14.04% return on equity
Mercury General Corporation, together with its subsidiaries, engages in writing personal automobile insurance in the United States. It also writes homeowners, commercial automobile, commercial property, mechanical protection, fire, and umbrella insurance. The company's automobile insurance products cover collision, property damage, bodily injury, comprehensive, personal injury protection, underinsured and uninsured motorist, and other hazards; and homeowners' insurance products cover dwelling, liability, personal property, fire, and other hazards. It sells its policies through a network of independent agents, 100% owned insurance agents, and direct channels in Arizona, California, Florida, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas, and Virginia. The company was founded in 1961 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, Mercury General Corporation has a trailing twelve months EPS of $3.89.
PE Ratio
Mercury General Corporation has a trailing twelve months price to earnings ratio of 14.49. Meaning, the purchaser of the share is investing $14.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.04%.
2. Molina Healthcare (MOH)
20.5% sales growth and 27.53% return on equity
Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.
Earnings Per Share
As for profitability, Molina Healthcare has a trailing twelve months EPS of $18.43.
PE Ratio
Molina Healthcare has a trailing twelve months price to earnings ratio of 15.7. Meaning, the purchaser of the share is investing $15.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.53%.
Moving Average
Molina Healthcare’s value is below its 50-day moving average of $313.58 and way below its 200-day moving average of $355.00.
Yearly Top and Bottom Value
Molina Healthcare’s stock is valued at $289.27 at 01:22 EST, way under its 52-week high of $423.92 and higher than its 52-week low of $283.53.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 0.5% and positive 23.8% for the next.
Volume
Today’s last reported volume for Molina Healthcare is 182863 which is 65.35% below its average volume of 527796.
3. Ceragon Networks Ltd. (CRNT)
17.6% sales growth and 3.61% return on equity
Ceragon Networks Ltd. provides wireless backhaul solutions that enable cellular operators and other wireless service providers to deliver voice and data services. Its wireless backhaul solutions use microwave and millimeter wave technology to transfer telecommunication traffic between base stations, small/distributed cells, and the core of the service provider's network. The company also offers wireless fronthaul solutions that use microwave technology for ultra-high speed, ultra-low latency communication for wireless 5G and 4G base stations. In addition, it provides IP-20 all-outdoor solutions, such as IP-20C, IP-20C-HP, IP-20S, IP-20E, and IP-20V; IP-20 split-mount/all-indoor solutions comprising IP-20N/IP-20A, IP-20F, and IP-20G; and IP-50 disaggregated solutions, including IP-50E, IP-50C, IP-50S, and IP-50FX for various short-haul, long-haul, fronthaul, and enterprise access applications. Further, the company offers network management system; and network and radio planning, site survey, solutions development, installation, network auditing and optimization, maintenance, training, and other services. It provides its services to smart-phone applications, such as internet browsing, social networking, image sharing, music, and video applications; oil and gas companies; public safety organizations; business and public institutions; broadcasters; energy utilities; and private communications networks. The company sells its products through direct sales, original equipment manufacturers, resellers, distributors, and system integrators. It operates in North America, Europe, Africa, the Asia Pacific, the Middle East, India, and Latin America. The company was formerly known as Giganet Ltd. and changed its name to Ceragon Networks Ltd. in September 2000. Ceragon Networks Ltd. was incorporated in 1996 and is headquartered in Tel Aviv, Israel.
Earnings Per Share
As for profitability, Ceragon Networks Ltd. has a trailing twelve months EPS of $0.05.
PE Ratio
Ceragon Networks Ltd. has a trailing twelve months price to earnings ratio of 54.6. Meaning, the purchaser of the share is investing $54.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.61%.
Yearly Top and Bottom Value
Ceragon Networks Ltd.’s stock is valued at $2.73 at 01:22 EST, way under its 52-week high of $3.38 and way higher than its 52-week low of $1.56.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 200% and 125%, respectively.
4. Progyny (PGNY)
15.7% sales growth and 12.3% return on equity
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Progyny has a trailing twelve months EPS of $0.61.
PE Ratio
Progyny has a trailing twelve months price to earnings ratio of 48.61. Meaning, the purchaser of the share is investing $48.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.3%.
Moving Average
Progyny’s value is higher than its 50-day moving average of $28.00 and way under its 200-day moving average of $33.50.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 13.3% and 25%, respectively.
5. ANSYS (ANSS)
13.9% sales growth and 8.53% return on equity
ANSYS, Inc. develops and markets engineering simulation software and services for engineers, designers, researchers, and students in the United States, Japan, Germany, China, Hong Kong, South Korea, rest of Europe, the Middle East, Africa, and internationally. It offers structural analysis product suite that provides simulation tools for product design and optimization; the Ansys Mechanical product, an element analysis software; LS-DYNA solver for multiphysics simulation; and power analysis and optimization software suite. The company also offers electronics product suite that provides electromagnetic field simulation software for designing electronic and electromechanical products; Ansys High Frequency Structure Simulator product for radio frequency and microwave design; SCADE product suite, a solution for embedded software simulation, code production, and automated certification; fluids product suite that enables modeling of fluid flow and other related physical phenomena; Ansys Fluent computational fluid dynamics software package; Ansys RedHawk-SC for electronic design automation; Ansys Optics software; and mission-simulation, modeling, testing, and analysis software. In addition, it offers Ansys Granta MI system for materials information management; Ansys Granta Selector technology for materials selection and graphical analysis; CES EduPack product, a set of teaching resources; Granta Materials Data for Simulation; Ansys Lumerical product, a photonics simulation software solution; safety-certified embedded software solutions; Discovery product family for use in the simulation of product design; academic product suite for research and teaching settings. ANSYS, Inc. was founded in 1970 and is headquartered in Canonsburg, Pennsylvania.
Earnings Per Share
As for profitability, ANSYS has a trailing twelve months EPS of $5.72.
PE Ratio
ANSYS has a trailing twelve months price to earnings ratio of 58.43. Meaning, the purchaser of the share is investing $58.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.53%.
Sales Growth
ANSYS’s sales growth for the next quarter is 13.9%.
Volume
Today’s last reported volume for ANSYS is 629906 which is 6.91% below its average volume of 676686.
6. Vertex Pharmaceuticals (VRTX)
8.2% sales growth and 24.38% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.89.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 28.55. Meaning, the purchaser of the share is investing $28.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.38%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 5.9% and a drop 0.5% for the next.
7. CBIZ (CBZ)
7.8% sales growth and 15.22% return on equity
CBIZ, Inc. provides financial, insurance, and advisory services in the United States and Canada. The company operates through three segments: Financial Services, Benefits and Insurance Services, and National Practices. The Financial Services segment offers accounting and tax, government healthcare consulting, financial advisory, valuation, and risk and advisory services. The Benefits and Insurance Services provides group health benefits consulting, payroll, property and casualty, and retirement plan services. The National Practices segment offers managed networking and hardware, and health care consulting services. It primarily serves small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises. The company was founded in 1987 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, CBIZ has a trailing twelve months EPS of $2.48.
PE Ratio
CBIZ has a trailing twelve months price to earnings ratio of 33.96. Meaning, the purchaser of the share is investing $33.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.22%.
8. Elbit Systems Ltd. (ESLT)
6.5% sales growth and 7.85% return on equity
Elbit Systems Ltd. develops and supplies a portfolio of airborne, land, and naval systems and products for the defense, homeland security, and commercial aviation applications primarily in Israel. The company offers military aircraft and helicopter systems; commercial aviation systems and aerostructures; unmanned aircraft systems; electro-optic, night vision, and countermeasures systems; naval systems; land vehicle systems; munitions, such as precision munitions for land, air, and sea applications; command, control, communications, computer, intelligence, surveillance and reconnaissance, and cyber systems; electronic warfare and signal intelligence systems; and other commercial activities. It also manufactures and sells data links and radio communication systems and equipment, and cyber intelligence, autonomous, and homeland security solutions; laser systems and products; guided rocket systems; and armored vehicle and other platforms survivability and protection systems, as well as provides various training and support services. The company markets its systems and products as a prime contractor or subcontractor to various governments and companies. It also has operations in the United States, Europe, Latin America, the Asia-Pacific, and internationally. The company was incorporated in 1966 and is based in Haifa, Israel.
Earnings Per Share
As for profitability, Elbit Systems Ltd. has a trailing twelve months EPS of $5.06.
PE Ratio
Elbit Systems Ltd. has a trailing twelve months price to earnings ratio of 36.97. Meaning, the purchaser of the share is investing $36.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.85%.
Volume
Today’s last reported volume for Elbit Systems Ltd. is 14577 which is 45.05% below its average volume of 26532.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 18, 2024, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 1.07%.
